Background and Purpose-EmboTrap is a novel stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke secondary to large-vessel occlusions. Here, we evaluated EmboTrap's safety and efficacy compared with established stent retrievers. Methods-ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was a single-arm, prospective, multicenter study, comparing the EmboTrap device to a composite performance goal criterion derived using a Bayesian meta-analysis from the pivotal SWIFT (Solitaire device) and TREVO 2 (Trevo device) trials. Patients at 11 US and 8 European sites were eligible for inclusion if they had large-vessel occlusions and moderate-to-severe neurological deficits within 8 hours of symptom onset. The primary efficacy end point was achievement of modified Thrombolysis in Cerebral Ischemia (mTICI) reperfusion scores of ≥2b within 3 EmboTrap passes as adjudicated by the core laboratory. The primary safety end point was a composite of symptomatic intracerebral hemorrhage and serious adverse device effects. Secondary end points included functional independence (modified Rankin Scale, 0-2) and all-cause mortality at 90 days. Results-Between October 2015 and February 2017, 227 patients were enrolled and treated with the EmboTrap device. The primary efficacy end point (mTICI ≥2b within 3 passes) was achieved in 80.2% (95% confidence interval, 74%-85% versus 56% performance goal criterion; P value, <0.0001), and mTICI 2c/3 was 65%. After all interventions, mTICI 2c/3 was achieved in 76%, and mTICI ≥2b was 92.5%. The rate of first pass (mTICI ≥2b following a single pass) was 51.5%. The primary safety end point composite rate of symptomatic intracerebral hemorrhage or serious adverse device effects was 5.3%. Functional independence and all-cause mortality at 90 days were 67% and 9%, respectively. Conclusions-The EmboTrap stent-retriever mechanical thrombectomy device demonstrated high rates of substantial reperfusion and functional independence in patients with acute ischemic stroke secondary to large-vessel occlusions. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT02488915.
Stroke
May 2018 R ecent landmark acute ischemic stroke (AIS) trials have demonstrated the clinical benefit and superior reperfusion efficacy of endovascular therapy using stent-retriever thrombectomy devices. [1] [2] [3] [4] Presently, these devices are now considered the standard of care for treatment of AIS secondary to large-vessel occlusion. 5 In a pooled, individual participant data meta-analyses of these trials, the rate of successful reperfusion (defined as modified Thrombolysis in Cerebral Ischemia [mTICI] ≥2b 6 ) was 71%, whereas the rate of final complete reperfusion (mTICI, 3) was only 33%. 7, 8 However, given the ≈30% rate of failed reperfusion and only one third of patients achieving final complete reperfusion after all interventions, further advances in mechanical thrombectomy are warranted. Moreover, opportunities exist to increase the rate of near-complete reperfusion (mTICI, ≥2c) from a single pass (eg, first-pass [FP] success), which has been shown to improve patient outcomes (90-day functional independence rates of 61.3% versus 35.3% in non-FP success). 9 The EmboTrap reperfusion device (Neuravi/Cerenovus) is a dual-layer stent retriever, engineered with articulating petals, and a distal capture zone for effectively trapping, retaining, and removing various clot types to restore blood flow in patients with AIS secondary to large-vessel occlusion ( Figure 1A ). 10 It is designed for use in cerebral circulations with promising results from the first in-person clinical experience.
ARISE II (Analysis of Revascularization in Ischemic Stroke
With EmboTrap) was an open-label, single-arm, multicenter, prospective clinical study designed to evaluate the safety and efficacy of the EmboTrap device in patients with AIS compared with a performance goal (PG) established using adjudicated efficacy rates for the FDA-approved predicate stent-retriever devices, Solitaire (Medtronic) and Trevo (Stryker).
12,13

Methods
Study Design
The data that support the findings of this study are available from the corresponding author on reasonable request and with approval from the ARISE II investigators. The primary ARISE II study hypothesis was the superiority of the EmboTrap device successful reperfusion performance in the treated population within 3 attempts as compared with a composite PG criterion derived using Bayesian meta-analysis of the pivotal SWIFT (SOLITAIRE™ FR With the Intention for Thrombectomy) and TREVO 2 trials (Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke). The study was overseen by an executive committee, composed of academic investigators and statisticians, an independent clinical events committee, and an independent data and safety monitoring board. The data and safety monitoring board consisted of 2 stroke neurologists and 3 neurointerventionalists, who did not enroll patients, and a biostatistician. The data and safety monitoring board acted in an expert advisory capacity and monitored subject safety and the conduct of the study. The clinical events committee adjudicated all safety end points, including hemorrhages, dissections/perforations, and serious neurological adverse events. The sponsor, Neuravi, was responsible for logistical operations, data management, and monitoring of the trial. The study protocol was approved by the institutional review board or ethics committee at each participating site.
Population and Participating Centers
Enrollment occurred at 11 US and 8 European centers. Study centers were required to have participated in similar regulated studies within the past 12 months. All patients or their legally authorized representative provided written informed consent before enrollment. Patients aged 18 to 85 years were eligible for the study if they had AIS with moderate-to-severe neurological deficits, angiographically proven occlusion (mTICI, 0-1) in the internal carotid, middle cerebral (M1 or M2 segment), basilar, or vertebral artery, and could undergo endovascular therapy (at least 1 EmboTrap deployment) within 8 hours of symptom onset. Key inclusion criteria included prestroke modified Rankin Scale (mRS) ≤1, baseline National Institutes of Health Stroke Scale (NIHSS) score ≥8 and ≤25, Alberta Stroke Program Early CT Score (ASPECTS) ≥6 or core infarct volume <50 mL on magnetic resonance imaging or computed tomography-based imaging (for anterior circulation strokes), and treatment with intravenous tPA (tissuetype plasminogen activator; if eligible within 3 hours of stroke onset). Key exclusion criteria included stenosis or any occlusion in a proximal vessel requiring treatment or preventing access to the thrombus ( Table  I in the online-only Data Supplement). Results are presented on the treated population who were consented and enrolled after diagnostic angiography and received intervention with the EmboTrap.
Procedures
Arterial access and use of anesthesia was performed according to the standard practices of the study center. A baseline angiogram was obtained before device deployment to assess angiographic inclusion/ exclusion criteria. Patients undergoing angiography but not meeting study criteria were followed up for 72 hours after the procedure.
The EmboTrap was used in accordance with instructions for use ( Figure I in the online-only Data Supplement). A minimum of 1 deployment of the EmboTrap was required within 8 hours of symptom onset. Up to 3 passes of the EmboTrap were allowed to achieve successful reperfusion (mTICI, ≥2b). After the third attempt, rescue therapy could be used at the discretion of the operator. Rescue therapy was defined as the use of another mechanical thrombectomy device, mechanical pump aspiration, intracranial stenting, or initiation of intra-arterial tPA during the procedure. The primary efficacy end point angiogram was captured before the start of any rescue treatment and following the 3 device passes or at the end of the procedure (if <3 passes). If rescue therapy was used before 3 passes, the case was counted as a failure to achieve primary efficacy end point. Follow-up assessments were performed at 24 hours, 7 days, and 90 days. Computed tomography or magnetic resonance imaging was obtained 24 hours post-procedure to assess for any hemorrhage. Both NIHSS and mRS scores were obtained at the 7-and 90-day visits.
Outcomes
Primary Efficacy End Point
The degree of reperfusion was assessed by central readers using the mTICI scale with the addition of the 2c score. 6, 14 The primary efficacy end point was successful reperfusion, defined as achieving mTICI ≥2b in the target vessel within 3 passes of the EmboTrap device without the use of rescue therapy. Two experienced neurointerventionalist readers from the independent core laboratory adjudicated the angiograms and assessed the mTICI scores. If the 2 readers assigned a different score, a third experienced reader would adjudicate. The core laboratory scores were used for determination of primary efficacy end point.
Primary Safety End Point
The primary safety end point was a composite of symptomatic intracerebral hemorrhage (sICH) within 24 hours (−8/+12 hours) postprocedure, together with any serious adverse device effects (excluding those already counted in sICH). sICH was defined as any extravascular blood in the brain or within the cranium associated with clinical deterioration, as defined by a worsening NIHSS score of ≥4 points, or that led to death and was identified as the predominant cause of the neurological deterioration adjudicated by an independent clinical event committee. 15 All computed tomographic/magnetic resonance images were assessed by the independent core laboratory to detect and evaluate the occurrence of hemorrhages. All hemorrhages and serious adverse device effects reported in the study were reviewed and adjudicated by the clinical events committee.
Secondary End Points
Prespecified secondary end points included (1) functional independence, defined as a mRS score of 0 to 2 at 90 days; (2) procedure time, defined as time from puncture to achievement of mTICI ≥2b or, if not obtained, to the final angiogram; (3) time to treat, defined as time from first baseline angiogram to achievement of mTICI ≥2b or, if not obtained, to the final angiogram; (4) embolization in a previously uninvolved territory on angiogram; (5) sICH; (6) procedurerelated mortality rate at 7 days and all-cause mortality at 90 days; (7) rate of serious adverse device effect; and (8) rate of neurological deterioration by ≥4 points on NIHSS adjudicated by an independent clinical event committee.
Statistical Analysis
The trial was designed to investigate the performance of the EmboTrap device (P EmboTrap ) against a PG for efficacy (PGefficacy=0.56) derived from a Bayesian hierarchical random effects meta-analysis of reperfusion efficacy rates of approved predicate devices' core laboratory adjudicated performances as reported in the literature. The meta-analysis resulted in an average rate of 64% to which a margin of analysis of 8% was applied, hence a PG for efficacy of 56%. The test of effectiveness was based on a An evaluable sample size of 176 provided 90% power to demonstrate superiority to PG (PGefficacy) of 0.56, based on a 1-sided exact test for a binomial proportion at the 0.025 significance level and assuming that the proportion of adjudicated successes with the EmboTrap device is 0.68. The primary safety end point was evaluated descriptively, with an unadjusted 95% confidence interval (CI). Descriptive statistics were used for demographics, baseline characteristics, procedural information, and clinical outcomes (efficacy and safety). All CIs for binary variables are ClopperPearson Exact binomial CIs, and those for continuous variables are based on a normal distribution assumption for the parameter of interest. Analysis was performed using SAS V9.4, R, SPSS, Minitab, and Stata.
Results
Between October 2015 and February 2017, 228 patients were enrolled in the study, and 227 subsequently underwent treatment with the EmboTrap. Figure 1B outlines the screening, enrollment, and treatment of the ARISE II-treated population.
The baseline characteristics are shown in Table 1 . The mean age was 68±13 years, 45.8% were men, and the mean baseline NIHSS was 15.8±5. The median (interquartile range [IQR]) baseline ASPECT score was 10 (9-10). Anterior circulation occlusion was encountered in 96% of patients, the most common location being the middle cerebral artery, M1 (55.5%) and M2 (25.1%), followed by internal carotid artery occlusion (15.4%). Over half of the patients (52.9%) received intravenous tPA. A balloon guide catheter was used in 73.6% of patients.
Key time metrics are presented in Figure 2A . The median time from symptom onset/last known well to puncture was 214 (IQR, 155-266) minutes and door-to-puncture was 60 (IQR, 36-93) minutes.
Primary Efficacy End Points and Reperfusion Results
The EmboTrap achieved the primary efficacy end point of successful reperfusion (mTICI ≥2b within 3 passes and without use of rescue therapy) in 182 of 227 (80.2%; 95% CI, 74%-85%) and demonstrated superiority to the preset PG criterion of 56% for efficacy (P value, <0.0001; Table 2 ). Three patients treated with rescue therapy before 3 EmboTrap passes were counted as failure.
The rate of mTICI ≥2c reperfusion within 3 EmboTrap passes was 64.8%. The full distribution of reperfusion outcomes is shown in Figure 2B . FP effect (mTICI ≥2c after a single pass) was seen in 91 of 227 (40.1%) and modified FP effect (mTICI ≥2b after a single pass) was seen in 117 of 227 (51.5%) patients.
Rescue therapy was used in 44 of 227 (19.4%) patients, including use of intra-arterial thrombolysis, other thrombectomy devices, and pump aspiration (Table II in the online-only Data Supplement).
Final angiographic reperfusion rates after all interventions were 92.5% mTICI ≥2b, 75.8% mTICI ≥2c, and 52.0% mTICI 3.
Primary Safety End Points
The primary safety composite end point rate of sICH postprocedure or serious adverse device effects was 5.3% (95% CI, 3%-9%; Table 3 ). All events were sICH.
Secondary End Points
Secondary outcomes are shown in Tables 2 and 3 . Functional independence (mRS, 0-2) at 90 days was achieved in 67.3% (146/217; 95% CI, 61%-73%). The full distribution of disability levels at 90 days is shown in Figure 2C . Neurological deterioration by ≥4 NIHSS points at 24 hours occurred in 4.5% (95% CI, 2%-9%). Procedure-related mortality rate at day 7 was 0% and all-cause mortality at day 90 was 9% (95% CI, 6%-14%). The median time to treat (interval from baseline angiogram to final post-EmboTrap angiogram) was 24 minutes (IQR, 13-46), whereas the procedure time was 36 minutes (IQR, 24-61; Figure 2A ). The rate of embolization into new territory on angiography was 6.6%. All adverse events are listed in Table III in the online-only Data Supplement.
Discussion
In this prospective, multicenter trial, the EmboTrap achieved high rates of reperfusion among patients with AIS with largevessel occlusion, with substantial reperfusion achieved in 8 of every 10 patients with the EmboTrap alone and after additional interventions, achieved in >9 of every 10 patients. The successful reperfusion rate exceeded the threshold required to demonstrate superiority when compared with the study set PG criterion derived from reperfusion rates achieved by the predicate Trevo and Solitaire retriever devices in their regulatory registration trials. 13, 15 In the present trial, the enrolled patients were largely similar to those in the comparator studies (Table IV in the online-only  Data Supplement) 13,15 A slightly higher proportion of ARISE II patients had M2 occlusions. Compared with proximal occlusions, M2 occlusions may differ in their response to endovascular intervention. A lower clot burden may increase the likelihood of reperfusion success in M2 occlusions, but their more distal location, smaller size, and accessibility can diminish the likelihood of reperfusion success. 16 However, the higher M2 rate in ARISE II did not affect the comparison with the prior trials because the reperfusion rate for M2 occlusions was not higher than those for occlusions in the other target vessels.
ARISE II patients were also treated earlier than in the comparator trials, reflecting the evolution of systems of care and quality programs focused on shortening door-to-puncture times. 17 Because early reperfusion success is associated with reduced infarct volumes and decreased global disability, 17 the faster treatment times likely contributed to the improved clinical outcomes in ARISE II.
The TREVO and Solitaire devices have been evaluated in numerous subsequent trials and prospective registries, some reporting higher rates of reperfusion than what was initially achieved in TREVO 2 and SWIFT studies. 18, 19 Although direct comparisons between the ARISE II results and many of the recent prospective trials are not possible, because of differing enrollment criteria and angiographic end points, the successful reperfusion rates and clinical outcomes in our study compare favorably with those in the more recent prospective studies of other mechanical thrombectomy devices. The SEER and HERMES individual patient data pooled analyses reported final mTICI ≥2b rates of 71.1% and 71%, respectively, whereas the current study reported rates of 80% (within 3 EmboTrap passes) and 92.5% at the end of the procedure. Approximately, 16 CT scan images were missing. ARISE indicates Analysis of Revascularization in Ischemic Stroke With EmboTrap; ASPECT, Alberta Stroke Program Early CT Score; CAD, coronary artery disease; CT, computed tomography; IQR, interquartile range; LWK, last known well; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SWIFT, SOLITAIRE™ FR With the Intention for Thrombectomy; and tPA, tissue-type plasminogen activator.
*Body mass index is reported as mean (SD) for SWIFT. †One protocol violation in the treated subject with NIHSS <8. ‡SWIFT NIHSS reported as median (range).
When considering these randomized efficacy trials individually, the final reperfusion success rate of ARISE II was similar to the SWIFT PRIME trial, 3 which yielded one of the highest rates of final mTICI ≥2b at 88% (Tables IV through VI in the online-only Data Supplement).
The EmboTrap also showed favorable performance on several measures indicating faster or more complete reperfusion, beyond successful reperfusion (mTICI, ≥2b). ARISE II evaluated the FP 6 reperfusion measures, indicating immediate achievement of reperfusion on a single device pass, (the first trial to have the FP measures adjudicated by the core laboratory). FP successful reperfusion (mTICI, ≥2b) was achieved in 50% and FP excellent reperfusion (TICI, ≥2c) in 4 of every 10 patients. The ARISE II FP rates compared favorably to the self-reported angiographic outcome data of 25% excellent reperfusion in the Solitaire and Trevo device retrospective registries. 6, 18 EmboTrap also showed high rates of TICI ≥2c in 64.8% of patients within 3 passes compared with 56.6% achieving final TICI ≥2c in the stent-retriever arm of the ASTER trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization). 20 Faster and more complete resolution of ischemia has been associated with improved outcomes. 17 The favorable reperfusion performance in ARISE II, along with other factors, such as patient selection, good ASPECT score, and speed of treatment, may potentially have contributed to the high rate of good long-term clinical outcomes. In the present study, two thirds of patients were functionally independent (mRS, 0-2) and one half were disability free (mRS, 0-1) at 3 months, which compared favorably with previous studies (Table V in the online-only Data Supplement).
The promising angiographic results in ARISE II may be related to the attributes of the EmboTrap design. The different device compartments may potentially enhance clot device interaction, the central microstent part allows a bypass flow channel, and the dense mesh distal end structure aims at reducing distal embolization. Other potential contributing factors may include increased operator experience with stent retrievers since their approval, the higher proportion of M2 and lower proportion of internal carotid artery target occlusions, 21 lower clinical severity (median NIHSS, 16 versus 18 in SWIFT and 19 in TREVO 2), inclusion of small core infarct volume, 22 earlier time from stroke onset to treatment, use of balloon guide catheters, 23 and differences between the study populations in unmeasured variables.
The safety of the EmboTrap device in the current study was within the range of recent stent-retriever trials. Although the definition of sICH differed between trials, the 5% rate of sICH in ARISE II was comparable with 2% and 4% sICH rates in SWIFT and TREVO 2 trials, 13, 15 respectively (Table VII in the online-only Data Supplement). The all-cause mortality rate at 90 days was 9%, which is remarkably low for patients presenting with severe neurological deficits (median NIHSS, 16) and compared favorably to SWIFT and TREVO 2 at 17% and 33%, respectively. 13, 15 These safety results support an acceptable benefit-risk profile for the device.
Limitations
Our study had several limitations. The study was a single-arm trial against an objective PG criterion derived from prior studies of other devices, rather than a randomized trial with an internal control group. This design limits precision in concluding how well the EmboTrap performs compared with any particular single comparator device. The clinical outcome evaluators and central imaging adjudicators were not blinded to device use, but the requirement for certified clinical raters and use of a central core laboratory with readings by at least 2 independent raters were designed to mitigate any resulting bias. Similarly, clot length and density, which has been associated with reperfusion success and clinical outcome in several studies, was not captured. 24 
Conclusions
This prospective, multicenter study of a novel stent retriever designed specifically to address a broader range of clot types demonstrated that the EmboTrap device alone achieved successful reperfusion in 8 of 10 patients and was superior to the preset performance criteria derived from predicate thrombectomy device trials. In addition, substantial reperfusion was achieved on a single pass in one half of patients, and, after ARISE indicates Analysis of Revascularization in Ischemic Stroke With EmboTrap; FPE, first-pass effect; IQR, interquartile range; mRS, modified Rankin Scale; and mTICI, modified Thrombolysis in Cerebral Ischemia.
*Three patients were treated with rescue therapy (before 3 EmboTrap passes) and were counted as failures.
†No missing angiographic data. ‡Final successful reperfusion was mTICI score of ≥2b in the target vessel on final angiogram.
§First-pass effect is defined as achieving an mTICI score of ≥2c and modified FPE as ≥2b on the first pass of the EmboTrap device, 1 of 3 rescue cases treated with embo trap and pump was used aspiration counted as success. *Unknown or missing data are excluded from the denominator. †The denominator included those with available data, for mortality, 5 patients completely lost for follow-up, and for neurological deterioration, it was only documented in 178 patients.
rescue therapies, substantial reperfusion was achieved in >9 in 10 of all patients. Functional independence at 90 days was achieved in two thirds of ARISE II study patients.
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